Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Centessa Pharmaceuticals (CNTA) Non Operating Income (2022 - 2026)

Centessa Pharmaceuticals has reported Non Operating Income over the past 4 years, most recently at $103000.0 for Q4 2025.

  • Quarterly Non Operating Income rose 102.6% to $103000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, up 272.55% year-over-year, with the annual reading at $2.9 million for FY2025, 272.55% up from the prior year.
  • Non Operating Income was $103000.0 for Q4 2025 at Centessa Pharmaceuticals, up from -$1.8 million in the prior quarter.
  • Over five years, Non Operating Income peaked at $5.4 million in Q2 2022 and troughed at -$4.0 million in Q4 2024.
  • The 4-year median for Non Operating Income is -$474000.0 (2022), against an average of -$116375.0.
  • Year-over-year, Non Operating Income crashed 1154.29% in 2023 and then surged 2232.47% in 2025.
  • A 4-year view of Non Operating Income shows it stood at -$70000.0 in 2022, then crashed by 1154.29% to -$878000.0 in 2023, then crashed by 351.94% to -$4.0 million in 2024, then skyrocketed by 102.6% to $103000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Non Operating Income are $103000.0 (Q4 2025), -$1.8 million (Q3 2025), and $3.6 million (Q2 2025).